Company Analysis Sino Biopharmaceutical Limited
1. Summary
Advantages
- Price (0.411 $) is less than fair price (0.4493 $)
- Dividends (4.61%) are higher than the sector average (1.72%).
- The stock's return over the last year (-1.2%) is higher than the sector average (-35.53%).
Disadvantages
- Current debt level 19.31% has increased over 5 years from 14.71%.
- The company's current efficiency (ROE=7.65%) is lower than the sector average (ROE=13.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Sino Biopharmaceutical Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0% | -0.4% | 2.4% |
| 90 days | -12.6% | -37.9% | 4.2% |
| 1 year | -1.2% | -35.5% | 25.4% |
SBMFF vs Sector: Sino Biopharmaceutical Limited has outperformed the "Healthcare" sector by 34.33% over the past year.
SBMFF vs Market: Sino Biopharmaceutical Limited has significantly underperformed the market by -26.57% over the past year.
Stable price: SBMFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SBMFF with weekly volatility of -0.0231% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.411 $) is lower than the fair price (0.4493 $).
Price not significantly lower than the fair price: The current price (0.411 $) is slightly lower than the fair price by 9.3%.
4.2. P/E
P/E vs Sector: The company's P/E (28.15) is lower than that of the sector as a whole (31.5).
P/E vs Market: The company's P/E (28.15) is lower than that of the market as a whole (46.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.72) is lower than that of the sector as a whole (3.36).
P/BV vs Market: The company's P/BV (1.72) is higher than that of the market as a whole (-8.99).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.51) is lower than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (2.51) is lower than that of the market as a whole (4.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (9.79) is lower than that of the sector as a whole (9.95).
EV/Ebitda vs Market: The company's EV/Ebitda (9.79) is lower than that of the market as a whole (25.22).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -3.17% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-3.17%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (7.65%) is lower than that of the sector as a whole (13.19%).
ROE vs Market: The company's ROE (7.65%) is higher than that of the market as a whole (-8.21%).
5.5. ROA
ROA vs Sector: The company's ROA (3.67%) is lower than that of the sector as a whole (6.14%).
ROA vs Market: The company's ROA (3.67%) is lower than that of the market as a whole (4.86%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (40.18%) is higher than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (40.18%) is higher than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 4.61% is higher than the average for the sector '1.72%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 4.61% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 4.61% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (27.13%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
